The H2-receptor antagonist ranitidine interferes with clopidogrel-mediated P2Y12 inhibition in platelets

Pharmacological Research

Volumn 62, Issue 4, 2010, Pages 352-356

  Schäfer, Andreas ^a   Flierl, Ulrike ^a   Pförtsch, Stephanie ^a   Seydelmann, Nora ^a   Micka, Jan ^a   Bauersachs, Johann ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

ADP receptors; P2Y12; Platelet activation; PPI; Ranitidine

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; CLOPIDOGREL; PROSTAGLANDIN E2; PURINERGIC P2Y12 RECEPTOR; RANITIDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LOADING DRUG DOSE; MALE; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

AGED; BLOOD PLATELETS; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANITIDINE; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 77955271709     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.05.006     Document Type: Article

References (31)

1. Silber S., Albertsson P., Aviles F.F., Camici P.G., Colombo A., Hamm C., et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005, 26:804-847.
2. Smith S.C., Feldman T.E., Hirshfeld J.W., Jacobs A.K., Kern M.J., King S.B., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006, 113:156-175.
3. Qadeer M.A., Richter J.E., Brotman D.J. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings. J Hosp Med 2006, 1:13-20.
4. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301:937-944.
5. Schäfer A., Weinberger S., Flierl U., Eigenthaler M., Störk S., Walter U., et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008, 100:618-625.
6. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000, 84:891-896.
7. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
8. Wiviott S.D., Antman E.M. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation 2004, 109:3064-3067.
9. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
10. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
11. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119:2553-2560.
12. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Meneveau N., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
13. Trenk D., Hochholzer W., Fromm M.F., Chialda L.E., Pahl A., Valina C.M., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51:1925-1934.
14. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol 2008, 51:256-260.
15. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148-155.
16. Sibbing D., Morath T., Stegherr J., Braun S., Vogt W., Hadamitzky M., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009, 101:714-719.
17. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007, 50:1822-1834.
18. Blindt R., Stellbrink K., de Taeye A., Muller R., Kiefer P., Yagmur E., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007, 98:1329-1334.
19. Barragan P., Bouvier J.-L., Roquebert P.-O., Macaluso G., Commeau P., Comet B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phoshorylation. Catheter Cardiovasc Interv 2003, 59:295-302.
20. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
21. Frere C., Cuisset T., Quilici J., Camoin L., Carvajal J., Morange P.E., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007, 98:838-843.
22. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48:1742-1750.
23. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51:1404-1411.
24. Li X.Q., Andersson T.B., Ahlstrom M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004, 32:821-827.
25. Juurlink D.N., Gomes T., Ko D.T., Szmitko P.E., Austin P.C., Tu J.V., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180:713-718.
26. Stanek EJ, Aubert RE, Flockhart DA, Kreutz RP, Yao J, Breall JA et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel medco outcomes study. Presented at SCAI 2009 Las Vegas O-11; 2009 (Abstract).
27. Rassen J.A., Choudhry N.K., Avorn J., Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndromes. Circulation 2009, 120:2322-2329.
28. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K., et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008, 6:54-61.
29. O'Donoghue M.L., Braunwald E., Antman E.M., Murphy S.A., Bates E.R., Rozenman Y., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009.
30. Lev E.I., Ramabadran R.S., Guthikonda S., Patel R., Kleiman A., Granada J.F., et al. Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol 2007, 99:124-128.
31. Small D.S., Farid N.A., Li Y.G., Ernest C.S., Payne C.D., Salazar D.E., et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008, 24:2251-2257.